Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Cited by (2,225)

Items 101–200 of 2,225

1. PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
   Dave P. Nichols, Scott H. Donaldson, Carla A. Frederick, Steven D. Freedman, Daniel Gelfond, Lucas R. Hoffman, Andrea True Kelly, Michael R. Narkewicz, Jessica E. Pittman, Felix A. Ratjen et al. · 2021 · Journal of Cystic Fibrosis
2. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
   Valeria Capurro, Valeria Tomati, Elvira Sondo, Mario Renda, Anna Borrelli, Cristina Pastorino, Daniela Guidone, Arianna Venturini, Alessandro Giraudo, Sine Mandrup Bertozzi et al. · 2021 · International Journal of Molecular Sciences
3. Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis
   Lena Wucherpfennig, Simon M. F. Triphan, Sabine Wege, Hans‐Ulrich Kauczor, Claus Peter Heußel, Niclas Schmitt, Felix Wuennemann, Victoria L. Mayer, Olaf Sommerburg, Marcus Alexander Mall et al. · 2022 · Journal of Cystic Fibrosis
4. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial
   Claire Elizabeth Wainwright, Susanna A. McColley, Paul McNally, Michael Powers, Felix A. Ratjen, Jonathan H. Rayment, George Z. Retsch‐Bogart, Erica A. Roesch, Neil Ahluwalia, Anna Chin et al. · 2023 · American Journal of Respiratory and Critical Care Medicine
5. Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
   Lee, Rhianna E, Reidel, Boris, Nelson, Mark R, Macdonald, Jade K, Kesimer, Mehmet, Randell, Scott H · 2023 · Advanced Drug Delivery Reviews
6. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
   Kate M. O’Shea, Orla O’Carroll, Catherine Carroll, Brenda Grogan, Anna Connolly, Lynda O'Shaughnessy, Trevor T. Nicholson, Charles G. Gallagher, Edward F. McKone · 2020 · European Respiratory Journal
7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
   Kevin W Southern, J. Patrick Murphy, Ian P Sinha, Sarah J Nevitt · 2020 · Cochrane Database of Systematic Reviews
8. Modulators of CFTR. Updates on clinical development and future directions
   Emmanuelle Bardin, Alexandra Pastor, Michaëla Semeraro, Anita Golec, Kate Hayes, B. Chevalier, Farouk Berhal, Guillaume Prestat, Alexandre Hinzpeter, Christine Gravier‐Pelletier et al. · 2021 · European Journal of Medicinal Chemistry
9. Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases
   Matthias Griese · 2022 · Journal of Clinical Medicine
10. Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells
    Alexander A. Sousa, Colin F. Hemez, Lei Lei, Soumba Traore, Katarina Kulhánková, Gregory A. Newby, Jordan L. Doman, Keyede Oye, Smriti Pandey, Philip H. Karp et al. · 2024 · Nature Biomedical Engineering
11. Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
    Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, Renée Jensen, Lena P. Thia, Philip J. Robinson, Pornchai Tirakitsoontorn, Bonnie W. Ramsey, Marcus Alexander Mall, Jennifer L. Taylor‐Cousar et al. · 2025 · The Lancet Respiratory Medicine
12. New drug approvals for 2019: Synthesis and clinical applications
    Shuo Yuan, Bin Yu, Hong‐Min Liu · 2020 · European Journal of Medicinal Chemistry
13. Cystic fibrosis in low and middle-income countries (LMIC): A view from four different regions of the world
    Luiz Vicente Ribeiro Ferreira da Silva Filho, Marco Zampoli, Malena Cohen‐Cymberknoh, Sushil Kumar Kabra · 2020 · Paediatric Respiratory Reviews
14. Cardiovascular complications in cystic fibrosis: A review of the literature
    T. Spencer Poore, Jennifer L. Taylor‐Cousar, Edith T. Zemanick · 2021 · Journal of Cystic Fibrosis
15. The Changing Epidemiology of Cystic Fibrosis
    Pierre‐Régis Burgel, Espérie Burnet, Lucile Regard, Clémence Martin · 2022 · CHEST Journal
16. Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
    Zhongyu Liu, Justin D. Anderson, Lily Deng, Stephen Mackay, Johnathan Bailey, Latona Kersh, Steven Mark Rowe, Jennifer Susan Guimbellot · 2020 · Genes
17. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis
    Clémence Martin, Martine Reynaud‐Gaubert, Rébecca Hamidfar, I. Durieu, M. Murris‐Espin, Isabelle Danner‐Boucher, R. Chiron, Sylvie Leroy, Benoît Douvry, Dominique Grenet et al. · 2022 · Journal of Cystic Fibrosis
18. Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy
    Yunhua Peng, Jing Liu, Hiroyuki Inuzuka, Wenyi Wei · 2023 · Journal of Biological Chemistry
19. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
    Lucile Regard, Clémence Martin, Espérie Burnet, Jennifer Da Silva, Pierre‐Régis Burgel · 2022 · Cells
20. Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series
    Kate E. O'Connor, Dana L. Goodwin, Andrew NeSmith, Bryan A. Garcia, Christina M. Mingora, Sigrid Ladores, Steven Mark Rowe, Stefanie Krick, George Marty Solomon · 2021 · Journal of Cystic Fibrosis
21. Discovery of CFTR modulators for the treatment of cystic fibrosis
    Miquéias Lopes‐Pacheco, Nicoletta Pedemonte, Guido Veit · 2021 · Expert Opinion on Drug Discovery
22. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
    Nikoletta Kapouni, Maria Moustaki, Konstantinos Douros, Ioanna Loukou · 2023 · Children
23. The Clinical Use of Lung MRI in Cystic Fibrosis
    Gaël Dournes, Laura L. Walkup, Ilyès Benlala, Matthew M. Willmering, Julie Macey, S. Bui, François Laurent, Jason C. Woods · 2020 · CHEST Journal
24. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria
    Carlo Castellani, K. De Boeck, Elke De Wachter, Isabelle Sermet‐Gaudelus, Nicholas J. Simmonds, K.W. Southern · 2022 · Journal of Cystic Fibrosis
25. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
    Lindsay J. Caverly, Sebastián A. Riquelme, Katherine B. Hisert · 2022 · Clinics in Chest Medicine
26. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
    Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, I. Durieu, Véronique Houdouin, Camille Audousset, Julie Macey, Dominique Grenet, Michele Porzio, M. Murris‐Espin et al. · 2024 · The Lancet Respiratory Medicine
27. Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies
    Scott A. Kanner, Zunaira Shuja, Papiya Choudhury, Ananya Jain, Henry M. Colecraft · 2020 · Nature Methods
28. Theratyping cystic fibrosisin vitroin ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells
    Giovanni Sette, Stefania Lo Cicero, Giovanna Blaconà, Silvia Pierandrei, Sabina Maria Bruno, Valentina Salvati, Germana Castelli, Mario Falchi, Benedetta Fabrizzi, Giuseppe G. Cimino et al. · 2021 · European Respiratory Journal
29. The Changing Landscape of Nutrition in Cystic Fibrosis: The Emergence of Overweight and Obesity
    Julianna Bailey, Stefanie Krick, Kevin R. Fontaine · 2022 · Nutrients
30. Novel therapeutic approaches for the management of cystic fibrosis
    Ryan Jaques, Arslan Shakeel, Cameron Hoyle · 2020 · Multidisciplinary Respiratory Medicine
31. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy
    Katherine B. Hisert, Susan E. Birket, John Paul Clancy, Damian G. Downey, John F. Engelhardt, Isabelle Fajac, Robert D. Gray, Marrah E. Lachowicz-Scroggins, Nicole Mayer-Hamblett, Patrick H. Thibodeau et al. · 2023 · The Lancet Respiratory Medicine
32. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients
    Amir A. Moheet, Daniel J. Beisang, Lin Zhang, Scott D. Sagel, Jill M. VanDalfsen, Sonya L. Heltshe, Carla Frederick, Michelle Catherine Mann, Nicholas J. Antos, Joanne L. Billings et al. · 2020 · Journal of Cystic Fibrosis
33. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
    Nicole Mayer-Hamblett, David P. Nichols, Katherine Odem‐Davis, Kristin A. Riekert, Gregory S. Sawicki, Scott H. Donaldson, Felix A. Ratjen, Michael W. Konstan, Noah Simon, Daniel Rosenbluth et al. · 2021 · Annals of the American Thoracic Society
34. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
    Sophia Theres Pallenberg, Marie‐Madlen Pust, Ilona Rosenboom, Gesine Hansen, Lutz Wiehlmann, Anna‐Maria Dittrich, Burkhard Tümmler · 2022 · Microbiology Spectrum
35. Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Lijia Zhang, Dana P. Albon, Marieke Jones, Heather M. Bruschwein · 2022 · Therapeutic Advances in Respiratory Disease
36. Nutritional Care in Children with Cystic Fibrosis
    Elena Mariotti Zani, Roberto Grandinetti, Daniela Cunico, Lisa Torelli, Valentina Fainardi, Giovanna Pisi, Susanna Esposito · 2023 · Nutrients
37. Pulmonary Exacerbations in Adults With Cystic Fibrosis
    Gemma E. Stanford, Kavita Dave, Nicholas J. Simmonds · 2020 · CHEST Journal
38. A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis
    Alex Paynter, Umer Khan, Sonya L. Heltshe, Christopher Hooper Goss, Noah Lechtzin, Nicole Mayer-Hamblett · 2021 · Journal of Cystic Fibrosis
39. Review of CFTR modulators 2020
    Danielle Goetz, Adrienne P. Savant · 2021 · Pediatric Pulmonology
40. Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease
    Jonathan K. Alder, Rachel M. Sutton, Carlo J. Iasella, Mehdi syed Nouraie, Ritchie Koshy, Stefanie J. Hannan, Ernest G. Chan, Xiaoping Chen, Yingze Zhang, Mark J. Brown et al. · 2021 · The Journal of Heart and Lung Transplantation
41. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis
    Claudie Gabillard-Lefort, Michelle Casey, Arlene M. A. Glasgow, Fiona Boland, Orla Kerr, Elaine Marron, Anne Marie Lyons, Cedric Gunaratnam, Noel Gerard McElvaney, Emer P. Reeves · 2022 · American Journal of Respiratory and Critical Care Medicine
42. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
    Vincenzo Carnovale, Paola Iacotucci, Vito Terlizzi, Carmela Colangelo, Lorenza Ferrillo, Angela Pepe, Michela Francalanci, Giovanni Taccetti, Serena Buonaurio, Assunta Celardo et al. · 2022 · Journal of Clinical Medicine
43. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
    Caitlyn Harvey, Sinéad Weldon, J.S. Elborn, Damian G. Downey, Clifford C. Taggart · 2022 · International Journal of Molecular Sciences
44. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events
    Bonnie W. Ramsey, Christoph Ulrich Correll, David R. DeMaso, Edward F. McKone, Elizabeth D. Tullis, Jennifer L. Taylor‐Cousar, Chenghao Chu, Nataliya V. Volkova, Neil Ahluwalia, David Waltz et al. · 2023 · American Journal of Respiratory and Critical Care Medicine
45. Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance
    Kyung Duk Moon, Carmen Helena Coxon, Christine Årdal, Radu Botgros, Sarah Djebara, Laura Durno, Cara R. Fiore, Jean-Baptiste Perrin, Dennis M. Dixon, Marco Cavaleri · 2025 · Nature Communications
46. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS
    Lee, Tim, Sawicki, Gregory S., Altenburg, Josje, Millar, Stefanie J., Geiger, Jessica Morlando, Jennings, Mark T., Lou, Yiyue, McGarry, Lisa J., Van Brunt, Kate, Linnemann, Rachel W. · 2023 · Journal of Cystic Fibrosis
47. Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis
    Sanja Stanojevic, Katarina Vukovojac, Jenna R. Sykes, Felix A. Ratjen, Elizabeth D. Tullis, Anne L. Stephenson · 2020 · Journal of Cystic Fibrosis
48. The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
    Elvira Sondo, Federico Cresta, Cristina Pastorino, Valeria Tomati, Valeria Capurro, Emanuela Pesce, Mariateresa Lena, Michele Iacomino, Ave Maria Baffico, Domenico Antonio Coviello et al. · 2022 · International Journal of Molecular Sciences
49. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
    Francesca Saluzzo, Luca Riberi, Barbara Messore, Nicola Ivan Lorè, Iréne Esposito, Elisabetta Bignamini, Virginia De Rose · 2022 · Cells
50. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI
    Carmen Streibel, Corin Willers, Orso Pusterla, Grzegorz Bauman, Enno Stranzinger, Ben Brabandt, Oliver Bieri, Marion Curdy, Marina Bullo, Bettina Frauchiger et al. · 2023 · Journal of Cystic Fibrosis
51. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
    Enrico Costa, Silvia Girotti, Francesca Pauro, Hubert G. M. Leufkens, Marco Cipolli · 2022 · Orphanet Journal of Rare Diseases
52. Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations
    Georgia Mitropoulou, Angela Koutsokera, Chantal Csajka, Sylvain Blanchon, Alain Sauty, Jean-Francois Brunet, Christophe von Garnier, Grégory Resch, Benoit P. Guery · 2022 · European Respiratory Review
53. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis
    Baha Moshiree, Alvin Jay Freeman, Phuong T. Vu, Umer Khan, Carmen A. Ufret-Vincenty, Sonya L. Heltshe, Christopher Hooper Goss, Sarah Jane Schwarzenberg, Steven D. Freedman, Drucy Borowitz et al. · 2022 · Journal of Cystic Fibrosis
54. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation
    Yifat S. Oren, Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao, Jeong Shin Hong, Efrat Ozeri-Galai, Aurélie Hatton, Chen Leibson et al. · 2021 · Journal of Cystic Fibrosis
55. Trikafta and Psychopathology in Cystic Fibrosis: A Case Report
    William Tindell, Amanda E. Su, Sarah M. Oros, Abner O. Rayapati, Gopalkumar Rakesh · 2020 · Psychosomatics
56. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
    Linus Piehler, Ralf Thalemann, Christine Lehmann, Stephanie A. Thee, Jobst Fridolin Roehmel, Zulfiya Syunyaeva, Mirjam Stahl, Marcus Alexander Mall, Simon Y. Graeber · 2023 · Frontiers in Pharmacology
57. Synthetic Approaches to the New Drugs Approved during 2019
    Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma L. McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France et al. · 2021 · Journal of Medicinal Chemistry
58. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR
    Nesrine Baatallah, Ahmad Elbahnsi, Jean‐Paul Mornon, B. Chevalier, Iwona Maria Pranke, Nathalie Servel, Renaud Zelli, Jean‐Luc Décout, Aleksander Edelman, Isabelle Sermet‐Gaudelus et al. · 2021 · Cellular and Molecular Life Sciences
59. Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation
    Fabrizio Chiti, Jeffery W. Kelly · 2022 · Current Opinion in Structural Biology
60. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies
    Maya Desai, Chris Hine, Joanna L. Whitehouse, Keith Graham Brownlee, Susan C. Charman, Prasad Nagakumar · 2022 · Respiratory Medicine
61. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation
    Ido Sadras, Eitan Kerem, Galit Livnat, Ifat Sarouk, Oded Breuer, Joel M. Reiter, Alex Gileles‐Hillel, Ori Inbar, Michael Cohen, Ayelet Gamliel et al. · 2023 · Journal of Cystic Fibrosis
62. iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation
    Aarne Fleischer, Sara Vallejo‐Díez, José María Martín‐Fernández, Almudena Sánchez‐Gilabert, Mónica Castresana, Ángel del Pozo, Amaia Esquisabel, Sílvia Ávila, José Luis Castrillo, Eusebio Gaínza et al. · 2020 · Molecular Therapy — Methods & Clinical Development
63. A multimodal iPSC platform for cystic fibrosis drug testing
    Andrew C. Berical, Rhianna E. Lee, Junjie Lu, Mary Lou Beermann, Jake A. Le Suer, Aditya Mithal, Dylan Thomas, Nicole Ranallo, Megan Peasley, Alexander J. Stuffer et al. · 2022 · Nature Communications
64. Gene therapy for cystic fibrosis: Challenges and prospects
    Hongshu Sui, Xinghua Xu, Yanping Su, Zhaoqing Gong, Minhua Yao, Xiaocui Liu, Ting Zhang, Ziyao Jiang, Tianhao Bai, Junzuo Wang et al. · 2022 · Frontiers in Pharmacology
65. Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review
    L.R. Caley, H. White, Marcus Christofoor de Goffau, R. Andrés Floto, Julian Parkhill, Benjamin J. Marsland, Daniel Gavin Peckham · 2023 · Digestive Diseases and Sciences
66. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis
    Jennifer Loske, Mirjam Völler, Soeren Lukassen, Mirjam Stahl, Loreen Thürmann, Anke Seegebarth, Jobst Fridolin Roehmel, Sebastian Wisniewski, Marey Messingschlager, Stephan Lorenz et al. · 2024 · American Journal of Respiratory and Critical Care Medicine
67. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor
    Frédéric Becq, Sandra Mirval, Thomas Carrez, Manuella Lévêque, Arnaud Billet, Christelle Coraux, Édouard Sage, Anne Cantereau · 2021 · European Respiratory Journal
68. Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes
    Susheel K. Gunasekar, Litao Xie, Ashutosh Kumar, Juan Hong, Pratik Rajesh Chheda, Kang Chen, David M. Kern, Chau My-Ta, Joshua M Maurer, John Heebink et al. · 2022 · Nature Communications
69. Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor
    Evelyne Baroud, Nivedita Chaudhary, Anna M. Georgiopoulos · 2023 · Pediatric Pulmonology
70. Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications
    Zhen-Xi Niu, Jing Hu, Jinfeng Sun, Yatao Wang · 2024 · European Journal of Medicinal Chemistry
71. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells
    Wren E. Michaels, Robert J. Bridges, Michelle L. Hastings · 2020 · Nucleic Acids Research
72. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease
    Clémence Martin, Espérie Burnet, A. Ronayette-Preira, P. De Carli, J. Martin, L. Delmas, B. Prieur, Pierre‐Régis Burgel · 2021 · Respiratory Medicine and Research
73. Generation of functional ciliated cholangiocytes from human pluripotent stem cells
    Mina Ogawa, Jiaxin Jiang, Sunny Xia, Donghe Yang, Avrilynn Ding, Onofrio Laselva, Stephanie Chin, Marcela Hernandez, Changyi Cui, Yuichiro Higuchi et al. · 2021 · Nature Communications
74. The changing landscape of pediatric lung transplantation
    Nicholas Avdimiretz, Christian Benden · 2022 · Clinical Transplantation
75. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients
    Kathleen J. Ramos, Jennifer Susan Guimbellot, Maryam Valapour, Lauren Bartlett, Travis Hee Wai, Christopher Hooper Goss, Joseph M. Pilewski, Albert Faro, Joshua Matthew Diamond · 2022 · Journal of Cystic Fibrosis
76. Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond
    Marcus Alexander Mall, Gerard J. Criner, Marc Miravitlles, Steven Mark Rowe, Claus Franz Vogelmeier, David John Rowlands, Matthias Schoenberger, Pablo Altman · 2022 · European Respiratory Journal
77. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre
    Daniel H. Tewkesbury, Varinder Singh Athwal, Rowland J. Bright-Thomas, Andrew M. Jones, Peter James Barry · 2023 · Journal of Cystic Fibrosis
78. OrgaSegment: deep-learning based organoid segmentation to quantify CFTR dependent fluid secretion
    Juliet W. Lefferts, Suzanne Kroes, Matthew B. Smith, Paul J Niemöller, Natascha D.A. Nieuwenhuijze, Heleen N. Sonneveld van Kooten, Cornelis Korstiaan van der Ent, Jeffrey Matthijn Beekman, Sam F.B. van Beuningen · 2024 · Communications Biology
79. Phenotypes in Chronic Rhinosinusitis
    Justin P. McCormick, Harrison M. Thompson, Do‐Yeon Cho, Bradford Alan Woodworth, Jessica W. Grayson · 2020 · Current Allergy and Asthma Reports
80. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype
    Vincenzo Carnovale, Paola Iacotucci, Vito Terlizzi, Carmela Colangelo, Pietro Medio, Lorenza Ferrillo, Fabiola De Gregorio, Michela Francalanci, Giovanni Taccetti, Serena Buonaurio et al. · 2021 · Respiratory Medicine
81. Current state of CFTR modulators for treatment of Cystic Fibrosis
    Katherine A. Despotes, Scott H. Donaldson · 2022 · Current Opinion in Pharmacology
82. Toward a More Precise Future for Oncology
    Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
83. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis
    Meghan E. McGarry, Elizabeth R. Gibb, Gabriela R. Oates, Michael S. Schechter · 2021 · Paediatric Respiratory Reviews
84. Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
    Christie Mitri, Zhengzhong Xu, Pauline Bardin, Harriet Corvol, Lhousseine Touqui, Olivier Tabary · 2020 · Frontiers in Pharmacology
85. The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor
    Aaron C. Miller, Logan M Harris, Joseph E. Cavanaugh, Mahmoud H. Abou Alaiwa, David Anthony Stoltz, Douglas B. Hornick, Philip M. Polgreen · 2022 · Clinical Infectious Diseases
86. Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study
    Freddy J. Frost, Dilip S. Nazareth, Laurent Fauchier, Dennis Wat, James Shelley, Philip J. Austin, Martin John Walshaw, Gregory Y.H. Lip · 2023 · European Respiratory Journal
87. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis
    Emma L. Ledger, Daniel B. Smith, Jing Jie Teh, Michelle Wood, Page E Whibley, Mark Morrison, Joanna B. Goldberg, David W. Reid, Timothy J. Wells · 2024 · The Journal of Infectious Diseases
88. Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease
    Pierre‐Régis Burgel, Jean-Louis Paillasseur, I. Durieu, Martine Reynaud‐Gaubert, Rébecca Hamidfar, M. Murris‐Espin, Isabelle Danner‐Boucher, R. Chiron, Sylvie Leroy, Benoît Douvry et al. · 2024 · Annals of the American Thoracic Society
89. Development of elexacaftor – tezacaftor – ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis
    Peter Gordon Middleton, Jennifer L. Taylor‐Cousar · 2020 · Expert Review of Respiratory Medicine
90. Assays of CFTR Function In Vitro, Ex Vivo and In Vivo
    Anabela Santo Ramalho, Mieke Boon, Marijke Proesmans, François L. Vermeulen, Marianne Sylvia Carlon, K. De Boeck · 2022 · International Journal of Molecular Sciences
91. Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease
    Matthias Griese, Matthias Kappler, Florian Stehling, Johannes Schulze, Winfried Baden, Cordula Koerner‐Rettberg, Julia Carlens, Freerk Prenzel, Lutz Nährlich, Andreas Thalmeier et al. · 2022 · Orphanet Journal of Rare Diseases
92. Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension
    Susannah J. King, Audrey C. Tierney, Deirdre M. Edgeworth, D. Keating, E. Williams, Tom C. Kotsimbos, Brenda Button, John W. Wilson · 2021 · Nutrition
93. Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options
    Joanna Krajewska, Krzysztof Zub, Adam Słowikowski, Tomasz Zatoński · 2021 · European Archives of Oto-Rhino-Laryngology
94. Knowledge-based approaches to drug discovery for rare diseases
    Vinícius M. Alves, Daniel Korn, Vera Pervitsky, Andrew Thieme, Stephen J. Capuzzi, Nancy Baker, Rada Y. Chirkova, Sean Ekins, Eugene N. Muratov, Anthony James Hickey et al. · 2021 · Drug Discovery Today
95. Physical activity and exercise training in cystic fibrosis
    Thomas Radtke, Sherie J. Smith, Sarah J Nevitt, Helge U. Hebestreit, Susi Kriemler · 2022 · Cochrane Database of Systematic Reviews
96. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor
    Isabelle Fajac, Cori L. Daines, I. Durieu, Jennifer L. Goralski, Harry G.M. Heijerman, Christiane Knoop, Christof J. Majoor, Bote G. Bruinsma, Samuel M. Moskowitz, Valentin Prieto-Centurion et al. · 2022 · Journal of Cystic Fibrosis
97. The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy
    Philip M. Farrell, Michael J. Rock, Mei Wang Baker · 2020 · Genes
98. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
    Sheylan D. Patel, Taylor R. Bono, Steven Mark Rowe, George Marty Solomon · 2020 · European Respiratory Review
99. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial
    Scott D. Sagel, Umer Khan, Sonya L. Heltshe, John Paul Clancy, Drucy Borowitz, Daniel Gelfond, Scott H. Donaldson, Antoinette Moran, Felix A. Ratjen, Jill M. VanDalfsen et al. · 2020 · Annals of the American Thoracic Society
100. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
     Young Jin Kim, Nicole Sivetz, Jessica Layne, Dillon M. Voss, Lucia Yang, Qian Zhang, Adrian R. Krainer · 2022 · Proceedings of the National Academy of Sciences